Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Next Previous
Trial Profile

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALESIA
  • Sponsors Roche

    • Most Recent Events

    • 12 Sep 2023 Results comparing efficacy and safety of lorlatinib vs alectinib and brigatinib using matching adjusted indirect comparisons using patient level data from lorlatinib RCT (CROWN) to match the aggregate baseline characteristics of the comparator RCTs (alectinib: ALEX, ALESIA; brigatinib: ALTA-1L), presented at the 24th World Conference on Lung Cancer.
    • 14 Apr 2023 Planned End Date changed from 6 Dec 2019 to 31 Mar 2026.
    • 17 Jun 2021 Results of meta analysis from ALTA-1L, ALEX, CROWN, ALESIA and J-ALEX; comparing the relative efficacy of orlatinib, alectinib and brigatinib for patients with ALK inhibitor-naive or previously untreated ALK-positive advanced NSCLC, published in the Journal of Chemotherapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top